Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Status: | Recruiting |
---|---|
Conditions: | Lung Cancer, Lung Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 2/21/2019 |
Start Date: | January 28, 2019 |
End Date: | July 1, 2021 |
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with
genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV
non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.
genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV
non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and
partial) associated with rucaparib in patients with genomic LOH high and/or deleterious
BRCA1/2 mutations within: Cohort 1: Patients with squamous cell histology or mixed histology
with a squamous component; Cohort 2: Patients with non-squamous histology (adenocarcinoma,
large cell, or non-small cell lung cancer [NSCLC] not otherwise specified [NOS]).
SECONDARY OBJECTIVES:
I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival
(OS) associated with rucaparib within each cohort.
II. To evaluate duration of response among responders within each cohort. III. To evaluate
the frequency and severity of toxicities associated with rucaparib among all patients
enrolled on the study (combining cohorts).
TRANSLATIOAL MEDICINE OBJECTIVES:
I. To evaluate the association between alterations in deoxyribonucleic acid (DNA) repair
genes and response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
II. To perform comprehensive next-generation sequencing of circulating tumor DNA (ctDNA) at
baseline in all patients to assess its clinical utility in comparison to tumor tissue
biomarker profiles.
III. To establish a tissue/blood repository from patients with refractory non-small cell lung
cancer (NSCLC).
OUTLINE:
Patients receive rucaparib orally (PO) twice daily (BID) on days 1-21. Courses repeat every
21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, and
then every 6 months for up to 3 years.
I. To evaluate the overall response rate (ORR) (confirmed and unconfirmed, complete and
partial) associated with rucaparib in patients with genomic LOH high and/or deleterious
BRCA1/2 mutations within: Cohort 1: Patients with squamous cell histology or mixed histology
with a squamous component; Cohort 2: Patients with non-squamous histology (adenocarcinoma,
large cell, or non-small cell lung cancer [NSCLC] not otherwise specified [NOS]).
SECONDARY OBJECTIVES:
I. To evaluate investigator assessed progression-free survival (IA-PFS) and overall survival
(OS) associated with rucaparib within each cohort.
II. To evaluate duration of response among responders within each cohort. III. To evaluate
the frequency and severity of toxicities associated with rucaparib among all patients
enrolled on the study (combining cohorts).
TRANSLATIOAL MEDICINE OBJECTIVES:
I. To evaluate the association between alterations in deoxyribonucleic acid (DNA) repair
genes and response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
II. To perform comprehensive next-generation sequencing of circulating tumor DNA (ctDNA) at
baseline in all patients to assess its clinical utility in comparison to tumor tissue
biomarker profiles.
III. To establish a tissue/blood repository from patients with refractory non-small cell lung
cancer (NSCLC).
OUTLINE:
Patients receive rucaparib orally (PO) twice daily (BID) on days 1-21. Courses repeat every
21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, and
then every 6 months for up to 3 years.
Inclusion Criteria:
- Patients must meet all SCREENING/PRE-SCREENING and SUB-STUDY REGISTRATION COMMON
ELIGIBILITY CRITERIA as specified in S1400: Phase II/III Biomarker-Driven Master
Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
- Patients must be assigned to S1900A. S1900A biomarker eligibility defined as LOH high
and/or deleterious BRCA1/2 mutation is as follows using the Foundation Medicine Inc
(FMI) tissue- assay:
- LOH; alteration type: loss of heterozygosity (LOH); eligible alteration: Genomic
LOH >= 21%
- BRCA; alteration type: homologous recombination deficiency (HRD); eligible
alteration: Deleterious mutations in BRCA1 or BRCA2
- Patients must not have had prior treatment with any PARP inhibitor, including
rucaparib, talazoparib, veliparib, olaparib, or niraparib. For information and a list
of PARP inhibitors, please consult the S1900A ? Poly Polymerase Inhibitors, Scott et
al., 2015 JCO ref from the link on the S1900A protocol abstract page of the SWOG
(http://swog.org) or CTSU (https://www.ctsu.org) websites.
- Patients must be able to take oral medications.
- Patients must not have a >= Grade 3 hypercholesterolaemia (defined by National Cancer
Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5)
within 28 days prior to sub-study registration.
- Patients must not have EGFR sensitizing mutations, EGFR T790M mutation, ALK gene
fusion, ROS 1 gene rearrangement, and BRAF V600E mutation unless they have progressed
following all standard of care targeted therapy.
- Patients must not have documented evidence of acute hepatitis or have an active or
uncontrolled infection.
- Patients with a known history of human immunodeficiency virus (HIV) seropositivity:
- Must have undetectable viral load using standard HIV assays in clinical practice.
- Must have CD4 count >= 400/mcL.
- Must not require prophylaxis for any opportunistic infections (i.e., fungal,
mycobacterium avium complex [mAC], or pneumocystis pneumonia [PCP] prophylaxis).
- Must not be newly diagnosed within 12 months prior to sub-study registration.
- Patients must have progressed (in the opinion of the treating physician) following the
most recent line of therapy.
- Patients must not have received any prior systemic therapy (systemic chemotherapy,
immunotherapy or investigational drug) within 21 days prior to sub-study registration.
Patients must have recovered (=< Grade 1) from any side effects of prior therapy.
Patients must not have received any radiation therapy within 14 days prior to
sub-study registration.
- Patients must not be planning to receive any concurrent chemotherapy, immunotherapy,
biologic or hormonal therapy for cancer treatment while receiving treatment on this
study. Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for
diabetes and hormone replacement therapy) is acceptable.
- Patients must have measurable disease documented by computed tomography (CT) or
magnetic resonance imaging (MRI). The CT from a combined positron emission tomography
(PET)/CT may be used to document only non-measurable disease unless it is of
diagnostic quality. Measurable disease must be assessed within 28 days prior to
sub-study registration. Pleural effusions, ascites and laboratory parameters are not
acceptable as the only evidence of disease. Non-measurable disease must be assessed
within 42 days prior to sub-study registration. All disease must be assessed and
documented on the Baseline Tumor Assessment Form. Patients whose only measurable
disease is within a previous radiation therapy port must demonstrate clearly
progressive disease (in the opinion of the treating investigator) prior to
registration. CT and MRI scans must be submitted for central review via TRIAD.
- Patients must have a CT or MRI scan of the brain to evaluate for central nervous
system (CNS) disease within 42 days prior to sub-study registration. Patient must not
have leptomeningeal disease, spinal cord compression or brain metastases unless: (1)
metastases have been locally treated and have remained clinically controlled and
asymptomatic for at least 14 days following treatment, and prior to registration, AND
(2) patient has no residual neurological dysfunction and has been off corticosteroids
for at least 24 hours prior to sub-study registration.
- Patient must not have had a major surgery within 14 days prior to sub-study
registration. Patient must have fully recovered from the effects of prior surgery in
the opinion of the treating investigator.
- Absolute neutrophil count (ANC) >= 1,500/mcl (obtained within 28 days prior to
sub-study registration)
- Platelet count >= 100,000 mcl (obtained within 28 days prior to sub-study
registration)
- Hemoglobin >= 9 g/dL (obtained within 28 days prior to sub-study registration)
- Serum bilirubin =< Institutional Upper Limit of Normal (IULN). For patients with liver
metastases, bilirubin must be =< 5 x IULN (within 28 days prior to sub-study
registration)
- Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN
(if both ALT and AST are done, both must be < 2 IULN). For patients with liver
metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both
must be =< 5 x IULN) (within 28 days prior to sub-study registration)
- Patients must have a serum creatinine =< the IULN OR calculated creatinine clearance
>= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been
drawn and processed within 28 days prior to sub-study registration.
- Patients must have Zubrod performance status 0-1 documented within 28 days prior to
sub-study registration.
- Patients must not have any Grade III/IV cardiac disease as defined by the New York
Heart Association Criteria (i.e., patients with cardiac disease resulting in marked
limitation of physical activity or resulting in inability to carry on any physical
activity without discomfort), unstable angina pectoris, and myocardial infarction
within 6 months, or serious uncontrolled cardiac arrhythmia.
- Pre-study history and physical exam must be obtained within 28 days prior to sub-study
registration.
- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
Stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years.
- Patients must not be pregnant or nursing. Women/men of reproductive potential must
have agreed to use an effective contraceptive method during the study and 6 months
after study completion. A woman is considered to be of "reproductive potential" if she
has had menses at any time in the preceding 12 consecutive months. In addition to
routine contraceptive methods, "effective contraception" also includes heterosexual
celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy
prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal
ligation. However, if at any point a previously celibate patient chooses to become
heterosexually active during the time period for use of contraceptive measures
outlined in the protocol, he/she is responsible for beginning contraceptive measures
during the study and 6 months after study completion
- Patients must agree to have blood specimens submitted for circulating tumor DNA
(ctDNA).
- Patients must also be offered participation in banking and in the correlative studies
for collection and future use of specimens.
We found this trial at
491
sites
Roseville, California 95661
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Ryan D. Gentzler
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Michael A. Schwartz
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: John C. Ruckdeschel
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Principal Investigator: Khaled A. Tolba
Phone: 503-494-1080
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-539-2273
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-487-7447
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-486-6000
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-678-9000
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Anita Ravipati
Phone: 806-212-1985
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 715-623-9869
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Jennifer M. Suga
Phone: 877-642-4691
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0836
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Yujie Zhao
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Michael A. Schwartz
Phone: 305-674-2625
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-956-4132
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Braselton, Georgia 30517
Principal Investigator: Charles H. Nash
Phone: 770-219-8800
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
1501 Trousdale Drive
Burlingame, California 94010
Burlingame, California 94010
Principal Investigator: Ari D. Baron
Phone: 650-696-4487
Click here to add this to my saved trials
Burlington, North Carolina 27216
Principal Investigator: Vinay K. Gudena
Phone: 336-538-7725
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Rubina Qamar
Phone: 414-302-2304
Click here to add this to my saved trials
Burr Ridge, Illinois 60527
Principal Investigator: Kathy S. Albain
Phone: 708-216-9000
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Cameron Park, California 95682
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Canton, Michigan 48188
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Caro, Michigan 48723
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Castro Valley, California 94546
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
Click here to add this to my saved trials
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
31500 Telegraph Road
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Principal Investigator: Philip J. Stella
Phone: 734-712-3671
Click here to add this to my saved trials
Clinton, South Carolina 29325
Principal Investigator: Jeffrey K. Giguere
Phone: 864-241-6251
Click here to add this to my saved trials
Clive, Iowa 50325
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
12495 University Ave
Clive, Iowa 50325
Clive, Iowa 50325
(515) 358-9700
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Mercy Cancer Center - West Lakes When it comes to cancer care, there
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials